Novartis’ Kisqali receives US FDA approval to reduce risk of …
WEB15 hours ago · Novartis announced that the US Food and Drug Administration (FDA) has approved Kisqali (ribociclib) in combination with an aromatase inhibitor (AI) for the adjuvant treatment of people with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) stage II and III early breast cancer (EBC) at high risk of recurrence, including those with node-negative (N0) disease.
Merck gets US FDA approval for Keytruda plus pemetrexed
WEB19 hours ago · Merck, known as MSD outside of the United States and Canada, announced the US Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, in combination with pemetrexed and platinum chemotherapy, for the first-line treatment of adult patients with unresectable advanced or metastatic malignant pleural mesothelioma (MPM).
JB Pharma accelerates global expansion and diversifies into …
WEB20 hours ago · JB Pharma has announced significant strides in its strategic growth, diversifying into progressive therapies while strengthening its presence in international markets. Over the past three years, the company has seen robust growth, with revenue increasing at a 19% compound annual growth rate (CAGR ...
Study shows use of metformin in adults with diabetes linked to …
WEB11 hours ago · Adults who use the prescription drug metformin to treat their type 2 diabetes have a lower risk of developing long Covid or dying after a Covid-19 infection than people with diabetes who take other anti-diabetes medications, according to a large study supported by the National Institutes of Health (NIH). The findings, published in the journal ...
News - Pharmabiz.com
WEB1 day ago · Pharmabiz.com - India's most comprehensive online pharma news service. It provides updates on Indian pharma industry, allied sectors like hospitals & diagnostic services,pharma tenders, pharma projects, pharma export & import, pharma laws & documents, pharma policies, pharma events, pharma company profiles, pharma studies, pharma marketing.
Daiichi Sankyo & AstraZeneca's Enhertu gets US FDA …
WEBAug 20, 2024 · Daiichi Sankyo and AstraZeneca's Enhertu (fam-trastuzumab deruxtecan-nxki) has been granted Breakthrough Therapy Designation (BTD) in the US for the treatment of unresectable or metastatic hormone receptor positive HER2 low (IHC 1+ or IHC 2+/ISH-) or HER2 ultralow (IHC >0 <1+) breast cancer patients who have received either two lines of endocrine therapy in the metastatic setting, or one line ...
Pfizer, BioNTech receive US FDA approval & authorization for …
WEBAug 24, 2024 · Pfizer Inc. and BioNTech SE announced that the US Food and Drug Administration (FDA) has approved the supplemental Biologics License Application for individuals 12 years of age and older (COMIRNATY (Covid-19 Vaccine, mRNA), and granted emergency use authorization for individuals 6 months through 11 years of age (Pfizer-BioNTech Covid-19 Vaccine) of the companies’ Omicron KP.2-adapted 2024 ...
AstraZeneca’s Imfinzi plus chemotherapy receives US FDA …
WEBJun 18, 2024 · AstraZeneca’s Imfinzi (durvalumab) in combination with carboplatin and paclitaxel followed by Imfinzi monotherapy has been approved in the US as treatment for adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR).
Takeda’s vedolizumab receives US FDA approval to treat …
WEBApr 20, 2024 · Takeda announced that the US FDA has approved Entyvio (vedolizumab) subcutaneous administration for maintenance therapy in adults with moderately to severely active Crohn’s disease (CD) after induction therapy with intravenous (IV) Entyvio. The subcutaneous administration of Entyvio was also approved by US FDA in September 2023 for the maintenance treatment of adults with moderately to ...
Boehringer Ingelheim’s Cyltezo to treat multiple chronic …
WEBMay 3, 2024 · Boehringer Ingelheim Group, one of the largest producers of biologic medicines in the world, announced that the US Food and Drug Administration (FDA) has approved the high-concentration, citrate-free formulation of Cyltezo (adalimumab-adbm), the company's interchangeable biosimilar to Humira (adalimumab), to treat multiple chronic inflammatory diseases.